These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 17452962)
21. Pramlintide acetate. McQueen J Am J Health Syst Pharm; 2005 Nov; 62(22):2363-72. PubMed ID: 16278328 [TBL] [Abstract][Full Text] [Related]
22. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Ratner RE; Want LL; Fineman MS; Velte MJ; Ruggles JA; Gottlieb A; Weyer C; Kolterman OG Diabetes Technol Ther; 2002; 4(1):51-61. PubMed ID: 12017421 [TBL] [Abstract][Full Text] [Related]
23. Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes. Ceriello A; Piconi L; Quagliaro L; Wang Y; Schnabel CA; Ruggles JA; Gloster MA; Maggs DG; Weyer C Diabetes Care; 2005 Mar; 28(3):632-7. PubMed ID: 15735200 [TBL] [Abstract][Full Text] [Related]
24. Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial. Thompson RG; Peterson J; Gottlieb A; Mullane J Diabetes; 1997 Apr; 46(4):632-6. PubMed ID: 9075803 [TBL] [Abstract][Full Text] [Related]
25. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Riddle M; Frias J; Zhang B; Maier H; Brown C; Lutz K; Kolterman O Diabetes Care; 2007 Nov; 30(11):2794-9. PubMed ID: 17698615 [TBL] [Abstract][Full Text] [Related]
26. Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. Hollander P; Ratner R; Fineman M; Strobel S; Shen L; Maggs D; Kolterman O; Weyer C Diabetes Obes Metab; 2003 Nov; 5(6):408-14. PubMed ID: 14617226 [TBL] [Abstract][Full Text] [Related]
27. Pramlintide in the treatment of diabetes. Edelman SV; Darsow T; Frias JP Int J Clin Pract; 2006 Dec; 60(12):1647-53. PubMed ID: 17109671 [TBL] [Abstract][Full Text] [Related]
28. Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk. Hoogwerf BJ; Doshi KB; Diab D Vasc Health Risk Manag; 2008; 4(2):355-62. PubMed ID: 18561511 [TBL] [Abstract][Full Text] [Related]
29. Are you up-to-date on diabetes medications? Scemons D Nursing; 2007 Jul; 37(7):45-9; quiz 49-50. PubMed ID: 17603373 [TBL] [Abstract][Full Text] [Related]
30. Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus. Hoogwerf BJ Cleve Clin J Med; 2006 May; 73(5):477-84. PubMed ID: 16708716 [TBL] [Abstract][Full Text] [Related]
31. Diabetes distress and its association with clinical outcomes in patients with type 2 diabetes treated with pramlintide as an adjunct to insulin therapy. Peyrot M; Rubin RR; Polonsky WH Diabetes Technol Ther; 2008 Dec; 10(6):461-6. PubMed ID: 19049375 [TBL] [Abstract][Full Text] [Related]
33. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Weyer C; Maggs DG; Young AA; Kolterman OG Curr Pharm Des; 2001 Sep; 7(14):1353-73. PubMed ID: 11472273 [TBL] [Abstract][Full Text] [Related]
34. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Kolterman OG; Schwartz S; Corder C; Levy B; Klaff L; Peterson J; Gottlieb A Diabetologia; 1996 Apr; 39(4):492-9. PubMed ID: 8778001 [TBL] [Abstract][Full Text] [Related]
35. Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data. Kruger DF; Gloster MA Drugs; 2004; 64(13):1419-32. PubMed ID: 15212559 [TBL] [Abstract][Full Text] [Related]
36. Therapies for diabetes: pramlintide and exenatide. Jones MC Am Fam Physician; 2007 Jun; 75(12):1831-5. PubMed ID: 17619527 [TBL] [Abstract][Full Text] [Related]
37. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Hollander P; Maggs DG; Ruggles JA; Fineman M; Shen L; Kolterman OG; Weyer C Obes Res; 2004 Apr; 12(4):661-8. PubMed ID: 15090634 [TBL] [Abstract][Full Text] [Related]
38. Pramlintide reduces the risks associated with glucose variability in type 1 diabetes. Kovatchev BP; Crean J; McCall A Diabetes Technol Ther; 2008 Oct; 10(5):391-6. PubMed ID: 18715216 [TBL] [Abstract][Full Text] [Related]
39. Psychometric properties of an instrument for assessing treatment satisfaction associated with pramlintide use. Rubin RR; Peyrot M Diabetes Educ; 2009; 35(1):136-46. PubMed ID: 19244569 [TBL] [Abstract][Full Text] [Related]
40. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus. Singh-Franco D; Robles G; Gazze D Clin Ther; 2007 Apr; 29(4):535-62. PubMed ID: 17617279 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]